SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor is trending following news of initiatives aimed at lowering mortgage rates, which the community broadly anticipates will ignite a housing market comeback. Investors are actively discussing a potential short squeeze and rapid price appreciation, believing that increased transaction activity from more accessible mortgage rates will directly benefit Opendoor's business model.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

Crow with knife ($CAW) is seeing a surge in community conversation, highlighted by its multi-chain presence across Solana, Cronos, and Base, utilizing deflationary tokenomics via bridging. The enthusiastic community is actively discussing its mission to become a dominant meme coin, aiming to challenge and surpass current market leaders.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is experiencing intense discussion as investors eagerly await its anticipated BLA resubmission to the FDA for deramiocel, following robust Phase 3 HOPE-3 trial results in Duchenne muscular dystrophy. Bulls are confident the compelling efficacy data, particularly for cardiac and limb function, will lead to approval, viewing recent price fluctuations as opportunities. Meanwhile, a polarized community is scrutinizing the submission timeline and significant options activity, with some expressing concerns over potential regulatory responses.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics (MLTX) is trending following positive FDA feedback, confirming its lead drug, sonelokimab, can proceed with a Biologics License Application using existing trial data, significantly de-risking its path to market. This regulatory clarity has ignited community discussion around potential analyst upgrades, a significant short squeeze, and heightened anticipation for a lucrative buyout, particularly from Merck, given its "best-in-class" asset status.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is experiencing significant bullish momentum, largely driven by a recent Bank of America upgrade and widespread community dismissal of a prior bearish analyst report. Investors are actively discussing expectations for imminent news regarding the BlueBird 6 satellite's unfurling and an accelerated deployment schedule, reinforcing conviction in the company's patented direct-to-device cellular broadband technology and its long-term potential in space communications.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is trending due to its persistent underperformance and recent analyst downgrades, intensifying a fierce community debate about whether its current low valuation represents a deep value opportunity or a long-standing value trap. Many express frustration with management and the stock's inability to rally despite strong cash flow and ongoing buybacks, particularly given its historical underperformance against broader market and fintech peers.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo Inc. is trending after announcing a landmark agreement with Meta Platforms to develop a 1.2 GW nuclear power campus for AI data centers, which is widely seen as a significant validation for advanced nuclear technology. While many in the community anticipate a short squeeze and substantial price appreciation, others remain cautious, pointing to the long-term timeline for revenue generation and the company's current valuation. This development underscores the growing necessity for stable, massive-scale power solutions as demand from the AI sector rapidly intensifies.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy (MSTR) is a focal point of market discussion, as the recent MSCI decision to retain digital-asset firms in its indexes provides a catalyst amid its tight correlation to Bitcoin's volatile movements. The community is sharply divided; bulls anticipate a potential short or gamma squeeze fueled by options activity and MSTR's discount to its underlying Bitcoin holdings, while bears emphasize ongoing share dilution and its occasional decoupling from BTC's rallies.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is experiencing significant bearish pressure, notably from a Bank of America downgrade and heightened competition in the weight-loss market with Amazon Pharmacy now offering Novo Nordisk's oral GLP-1 pill. The community is sharply divided, with many expressing deep frustration over consistent daily declines, while others view the current valuation as an attractive buying opportunity, emphasizing the company's fundamental growth, international expansion, and high short interest. Discussions center on whether the stock is a falling knife or poised for a rebound, as investors weigh core business strength against competitive headwinds in the evolving telehealth and GLP-1 sectors.

UWM Holdings Corp. is a wholesale mortgage lender, which underwrites and provides closing documentation for residential mortgage loans originated by independent mortgage brokers, correspondents, small banks and local credit unions. The firm provides independent mortgage advisors with a set of technologically driven tools and a value proposition that enables them to offer borrowers that meet the credit rating standards compelling financing alternatives. The company was founded in 1986 and is headquartered in Pontiac, MI.

UWM Holdings Corporation - Ordinary Shares - Class A

UWM Holdings is trending amid recent news regarding a government initiative to purchase mortgage bonds, which has ignited community optimism for lower rates and a potential boost in mortgage activity. Investors are actively discussing this catalyst, alongside persistent concerns about the CEO's share sales and the strategic impact of the company's recent acquisition.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biodexa Promotes Fiona Sharp To CFO As Stephen Stamp Cedes Role To Become Only CEO

(RTTNews) - Biodexa Pharmaceuticals Plc (BDRX), a clinical stage biopharmaceutical company, Monday announced that it has promoted Fiona Sharp to Chief Financial Officer and Company Secretary...

Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Upgraded to Buy: What Does It Mean for the Stock?

Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Shares of Biodexa Pharmaceuticals skyrocketed nearly 50% on Monday, hitting their highest level since early December.&nbsp;The Cardiff, UK-based company's stock surge followed the U.S. FDA granting its treatment eRapa a Fast Track designation.&nbsp;The drug, a proprietary encapsulated form of rapamycin, is being developed for familial adenomatous polyposis (FAP), a condition that, if left untreated, universally leads to colorectal cancer.&nbsp;FAP currently has no effective medical treatment, with the only option being surgical resection of the colon or rectum.The Fast Track designation aims to expedite the development and review of drugs targeting serious conditions with significant unmet medical needs.&nbsp;Biodexa's Phase 2 study of eRapa showed promising results, with a median 17% reduction in total polyp burden and a 75% non-progression rate at 12 months.&nbsp;In cohort 2, patients showed an even better response, with a 29% median reduction in polyp burden and an 89% non-progression rate.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/BDRX_sentiment_and_message_volume_Feb_10_2beb98885a.png" alt="BDRX sentiment and message volume Feb 10.png" width="1318" height="324"><figcaption>BDRX sentiment and message volume Feb 10 as of 1:45 pm ET | source: Stocktwits</figcaption></figure>On Stocktwits, retail sentiment turned 'extremely bullish,' with the stock soaring to the top 10 trending symbols. The volume of messages spiked to its highest level in a year, reflecting increased excitement among investors.&nbsp;Users were optimistic about the stock's potential, with one commenting that it could hit $10 and another suggesting that it was a "last chance to buy in before it goes above $8."&nbsp;<stembedurl>https://stocktwits.com/BULLNATION1/message/603560053</stembedurl><stembedurl>https://stocktwits.com/Mr_Xray/message/603579405</stembedurl>Biodexa's stock has gained around 57% so far this year, though it is still down more than 80% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a stock chart | Image source: Maria Korneeva on Getty Images

Biodexa Stock Surges On FDA's Fast-Track Tag For Treatment Of Cancer-Causing Condition: Retail Confidence Peaks

The drug, a proprietary encapsulated form of rapamycin, is being developed for familial adenomatous polyposis (FAP), a condition that, if left untreated, universally leads to colorectal cancer. 

Equity

Biodexa Pharmaceuticals Plc is a drug delivery technology company. It is focused on the research and development of medicines for rare cancers, via both in-house programs as well as partnered programs. The firm's proprietary platform drug delivery technologies are Q-Sphera platform is a disruptive polymer microsphere technology, which is used for sustained release at the microscale to prolong and control the release of therapeutics over an extended period of time from weeks to months; Midasolve platform is an innovative nano saccharide technology, which is used to dissolve drugs at the nanoscale so that they can be administered in liquid form directly and locally into tumors; Midacore platform is an edge gold nanoparticle technology, which is used for targeting sites of disease at the nanoscale. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Biodexa Pharmaceuticals Plc - ADR

Yes — Rates Move Meaningfully Lower

Short-Term Dip, No Lasting Impact

No — Mostly Political Noise

Other – Comment Below

President Trump says he’s directing $200 billion into mortgage bond purchases to bring down rates and improve housing affordability. With questions around execution, authority, and real market impact, do you think this move will actually lower mortgage rates in 2026?

Will Trump’s Mortgage Bond Plan Actually Lower Rates in 2026?

Current Price	$2.35
Prev Close	$2.31
Open	$2.37
Dividend Yield	0.00%
50-Day Moving Average	$4.60
Beta	1.21
Avg. Volume	2.63M
PE Ratio	-0.04

52-Week High	$92.00
52-Week Low	$2.22
Market Capitalization	$1.43M
EPS (Annual)	-$148.23
Price to Book	5.43
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

BDRX
Biodexa Pharmaceuticals Plc

Feed

News

Sentiment

Fundamentals

Info

Latest BDRX News

BDRXBiodexa Pharmaceuticals Plc